David O’Neill, PhD


David O’Neill brings extensive experience in Pharma, Biotech and seed stage investing to his role as President of FACIT.  Dr. O’Neill has a wealth of networks and transaction experience through various business development roles at AstraZeneca, Ambit Biosciences (Daiichi Sankyo), Kinomescan (Discoverx/Eurofins), Fluorinov Pharma (Trillium Therapeutics).  He also held operational roles including non-clinical safety, IND submission and Project Leader during clinical development of Quizartinib.  He has provided interim executive management to FACIT spin outs Turnstone Biologics, Propellon and Novera Therapeutics. In addition to serving on the Board of Triphase Accelerator and Cellular Analytics, he is also a Board Observer for Turnstone Biologics. Dr. O’Neill holds a PhD from Western University from the Faculty of Health Sciences with an emphasis on heat shock protein biology.


Other Team Members

Matthew Ward, MBA

Investment Analyst

Nicole Baryla, PhD

Senior Director, Corporate Affairs

Brent Zanke, MD, FRCPC, PhD